In the Media

In an article for The New York Times about the impact of patent laws on drug development, Austin Frakt highlights Prof. Benjamin Roin’s research that indicates pharmaceutical companies reject unpatentable drugs. To counter this problem, Frakt explains that Roin suggests “a period of market exclusivity…to any organization addressing an unmet medical need with a drug that isn’t patentable.”